PATENT CLAIM ANALYSIS

Application Number: 16163380
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-03
Patent Classification: ["424", "465000"]

Abstract:
The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Claim (Index 3):
The oral dosage form according to  claim 2  in the form of a tablet comprising a tablet core and a coating, wherein the d 6 -tetrabenazine and poly(ethylene oxide) polymer are in the tablet core.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 97.0
- Lexical Diversity: 1.02857
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14479823', '15071797', '14245024', '15044655', '14030322']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7929860079889783
- 35 USC 102 Novelty (BERT): 0.5809181105437953
- Combined Prediction Score: 0.77177921824446
- Mean Citation Score: 488.218912
- Max Citation Score: 508.84766
- Similarity Product: 351.3165247218978

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test